Study finds HPV vaccine cuts cervical cancer by nearly 90%
New, real world data shows the human papillomavirus, or HPV, vaccine cut cervical cancer rates among women in the U.K. by nearly 90%, according to a study published Wednesday in The Lancet.
Why it matters: Cervical cancer is the fourth most common cancer among women in the world, per the World Health Organization, killing more than 300,000 women each year.
By the numbers: The study estimates that by mid-2019, the HPV vaccine had prevented about 450 cancer and 17,200 pre-cancer diagnoses over 11 years, according to the study's funder, Cancer Research UK.
- The adults, who are now in their 20s, reported a 87% reduction in cervical cancer, according to the study.
- Those who got the vaccine between ages 14 and 16 saw a 62% reduced rate of cancer and cancerous conditions and those between 16 and 18 years old saw a 24% decrease risk, according to the study.
- The Centers for Disease Control and Prevention found that among vaccinated women, the percentage of cervical pre-cancer linked to cervical cancer dropped 40%.
Of note: The U.K.'s HPV vaccine program was launched in 2008 and targets girls between the ages of 11 and 13, per Cancer Research UK.
- The vaccine is most effective during this age range, "when someone is less likely to have been exposed to HPV," per Cancer Research UK.